Login to Your Account

Tesaro's PARP Inhibitor Enters Phase III Testing

By Catherine Shaffer
Staff Writer

Wednesday, July 24, 2013

Tesaro Inc., of Waltham, Mass., advanced its poly ADP-ribose polymerase (PARP) inhibitor, niraparib, for ovarian cancer into a Phase III. The double-blind, placebo-controlled trial, designated NOVA, began enrollment of patients with high-grade serous, platinum-sensitive, relapsed ovarian cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription